Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Hypomethylating agents (HMAs) in combination with venetoclax have been widely adopted as the standard of care for patients who cannot tolerate induction chemotherapy and for patients who have relapsed/refractory (R/R) acute myeloid leukemia (AML). This study retrospectively analyzed the outcomes of...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Hemasphere
Main Authors: Feld, Jonathan, Tremblay, Douglas, Dougherty, Mikaela, Czaplinska, Tina, Sanchez, Gillian, Brady, Claudia, Kremyanskaya, Marina, Bar-Natan, Michal, Keyzner, Alla, Marcellino, Bridget K., Gabrilove, Janice, Navada, Shyamala C., Silverman, Lewis R., El Jamal, Siraj M., Mascarenhas, John, Shih, Alan H.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2021
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7951133/
https://ncbi.nlm.nih.gov/pubmed/33718803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000549
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki